File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cervical ripening with Mifepristone (RU 486) in late first trimester abortion

TitleCervical ripening with Mifepristone (RU 486) in late first trimester abortion
Authors
Issue Date1994
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraception
Citation
Contraception, 1994, v. 50 n. 5, p. 461-475 How to Cite?
AbstractIn order to further evaluate the usefulness of the antiprogestogen, mifepristone, as a cervical ripening agent, a double-blind multicentre study was undertaken of 230 primigravid women with 10-12 weeks amenorrhoea who were randomly assigned to receive either 0 (placebo) or 200 mg of mifepristone 36 hours before surgical pregnancy termination. Fifteen women who did not fulfil all of the selection criteria were excluded from analysis. In the mifepristone group (N = 105) 12 women experienced some pre-operative vaginal bleeding as compared with only one subject in the placebo group (N = 210), but only one of these 22 women described the bleeding as more than her usual menstrual flow: In mifepristone-treated women the cervix was about 1 mm more dilated at operation and further mechanical dilatation was needed less frequently than in placebo-treated controls. High resistance during further mechanical stretching was encountered significantly mole often and at a smaller cervical diameter in the placebo group than in the women given mifepristone. Also, dilatation was reported by the operating surgeons to be easier in women given the antiprogestogen. Other significant differences included a shorter operation time, lower peroperative blood loss and less frequent use of analgesic drugs post-operatively in the mifepristone group. Post-operative complications, the duration of post-operative bleeding and the interval to the first menstruation were similar in both groups. The results confirm that the antiprogestogen, mifepristone, is an effective cervical ripening agent which deserves further study in comparison with the currently used methods, i.e. prostaglandins and osmotic dilators.
Persistent Identifierhttp://hdl.handle.net/10722/173200
ISSN
2015 Impact Factor: 2.788
2015 SCImago Journal Rankings: 1.557

 

DC FieldValueLanguage
dc.contributor.authorHenshaw, Ren_US
dc.contributor.authorBjornsson, Sen_US
dc.contributor.authorNorman, Jen_US
dc.contributor.authorHiibel, Ven_US
dc.contributor.authorGomez Alzugaray, Men_US
dc.contributor.authorHo, PCen_US
dc.contributor.authorBygdeman, Men_US
dc.contributor.authorHerczeg, Jen_US
dc.contributor.authorVan Look, PFAen_US
dc.contributor.authorBelsey, EMen_US
dc.contributor.authorBernersLee, Nen_US
dc.contributor.authorLaperriere, Nen_US
dc.contributor.authorVan Look, PFAen_US
dc.contributor.authorVon Hertzen, Hen_US
dc.contributor.authorBelsey, EMen_US
dc.date.accessioned2012-10-30T06:28:29Z-
dc.date.available2012-10-30T06:28:29Z-
dc.date.issued1994en_US
dc.identifier.citationContraception, 1994, v. 50 n. 5, p. 461-475en_US
dc.identifier.issn0010-7824en_US
dc.identifier.urihttp://hdl.handle.net/10722/173200-
dc.description.abstractIn order to further evaluate the usefulness of the antiprogestogen, mifepristone, as a cervical ripening agent, a double-blind multicentre study was undertaken of 230 primigravid women with 10-12 weeks amenorrhoea who were randomly assigned to receive either 0 (placebo) or 200 mg of mifepristone 36 hours before surgical pregnancy termination. Fifteen women who did not fulfil all of the selection criteria were excluded from analysis. In the mifepristone group (N = 105) 12 women experienced some pre-operative vaginal bleeding as compared with only one subject in the placebo group (N = 210), but only one of these 22 women described the bleeding as more than her usual menstrual flow: In mifepristone-treated women the cervix was about 1 mm more dilated at operation and further mechanical dilatation was needed less frequently than in placebo-treated controls. High resistance during further mechanical stretching was encountered significantly mole often and at a smaller cervical diameter in the placebo group than in the women given mifepristone. Also, dilatation was reported by the operating surgeons to be easier in women given the antiprogestogen. Other significant differences included a shorter operation time, lower peroperative blood loss and less frequent use of analgesic drugs post-operatively in the mifepristone group. Post-operative complications, the duration of post-operative bleeding and the interval to the first menstruation were similar in both groups. The results confirm that the antiprogestogen, mifepristone, is an effective cervical ripening agent which deserves further study in comparison with the currently used methods, i.e. prostaglandins and osmotic dilators.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraceptionen_US
dc.relation.ispartofContraceptionen_US
dc.rightsContraception. Copyright © Elsevier Inc.-
dc.subject.meshAbortion, Induceden_US
dc.subject.meshAdulten_US
dc.subject.meshCervix Uteri - Drug Effects - Physiologyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Adverse Effects - Pharmacologyen_US
dc.subject.meshPlacebosen_US
dc.subject.meshPregnancyen_US
dc.titleCervical ripening with Mifepristone (RU 486) in late first trimester abortionen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0010-7824(94)90063-9en_US
dc.identifier.pmid7859455-
dc.identifier.scopuseid_2-s2.0-0027988216en_US
dc.identifier.hkuros3113-
dc.identifier.volume50en_US
dc.identifier.issue5en_US
dc.identifier.spage461en_US
dc.identifier.epage475en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridHenshaw, R=7004042821en_US
dc.identifier.scopusauthoridBjornsson, S=7004925997en_US
dc.identifier.scopusauthoridNorman, J=7402489769en_US
dc.identifier.scopusauthoridHiibel, V=18535577400en_US
dc.identifier.scopusauthoridGomez Alzugaray, M=6506187382en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridBygdeman, M=7101634701en_US
dc.identifier.scopusauthoridHerczeg, J=7004223983en_US
dc.identifier.scopusauthoridVan Look, PFA=7005176694en_US
dc.identifier.scopusauthoridBelsey, EM=35885076200en_US
dc.identifier.scopusauthoridBernersLee, N=6507862311en_US
dc.identifier.scopusauthoridLaperriere, N=7004015563en_US
dc.identifier.scopusauthoridVan Look, PFA=35276238300en_US
dc.identifier.scopusauthoridVon Hertzen, H=7004390324en_US
dc.identifier.scopusauthoridBelsey, EM=24354727900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats